Blog
Published July 20, 2022
Summary
Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers
In contrast, biosimilar versions of adalimumab have been available in most countries outside the U.S. since 2018, resulting in high pricing disparities between immunology and inflammatory treatments between the U.S. and other markets
Trinity’s Take
Adalimumab biosimilar competition in Europe, as well as policy and payer pressure, has exerted downward pricing pressure for…
Read Now
Webinars
Available On Demand
Trinity invites forecasting executives in the life sciences industry to join us for a lively discussion on establishing a forecasting ecosystem:
How do you set up an ecosystem that houses market/competitor dynamics, product demand, market access, promotional efforts, contracting, returns/stocking/inventory information, etc…?
Once you have this ecosystem, what are some best practice approaches to having key stakeholders easily access and update?
Susheel Sukhtankar, Partner & Head of Commercial Analytics at Trinity, will host this session and moderate a panel with…
Watch Now
Webinars
Available On Demand
The demand for experienced talent coupled with changing work models during the pandemic has created a very competitive job market. Biopharma companies are challenged more than ever with how to recruit, retain and motivate talent.
Join Trinity Life Sciences for a webinar that explores the findings from our recent TGaS study entitled, ‘Recruiting, Retaining and Motivating Talent’. Interviews were conducted with 27 Chief Commercial Officers at pre-commercial and emerging companies to understand how the biopharma industry is addressing this significant…
Watch Now
White Papers
In 2018, Trinity Life Sciences published a white paper titled, How to Approach Asset Valuation in Pharma & Biotech: Putting a price tag on emerging therapies. At the time, pharma and biotech firms were seeing venture investment growth of ~20% per year. This trend has only accelerated alongside the value of co-developments, partnerships, joint ventures, licensing agreements and other deals nearly doubling from 2019 to 2020. Quantifying the value of underlying assets throughout the clinical development process remains vital to…
Read Now
Briefs
Throughout the first half of 2022, we’ve continued to face historic, unprecedented challenges related to the ongoing global pandemic. Life sciences enterprises, and essentially all industries, are grappling with decisions large and small. Priorities for Commercial, Market Access and Medical Affairs organizations in the life sciences industry continue to shift as teams work feverishly to evolve virtual and digital channels to engage with customers, and to sharpen Advanced Analytics. Developing capabilities and skills in new ways of working continue in…
Read Now
White Papers
The pharma industry has seen dramatic shifts in scientific innovation over the last decade with a trend toward orphan markets, personalized medicine, higher priced products and new modalities including cell and gene therapies, oligonucleotides and others. COVID served to further accelerate scientific innovation, driving a near record-breaking number of FDA approvals, astronomical venture capital funding and remarkably rapid development and rollout of ground-breaking products (including anti-virals, novel antibodies and mRNA vaccines). However, as Trinity Life Sciences discussed one year ago,…
Read Now
Briefs
While the vision and goal of patient centricity are clear, today’s leading life science companies are grappling with the complexities of execution: How to take the “idea” of patient centricity and translate it into strategy and tactics – and how to measure results.
Read our new advisory brief to learn more about our model and the concrete actions companies can do to integrate patient centricity into their business decisions.
Complete the form below to access the full brief
By submitting…
Read Now
Scientific Publications
Cremophor EL (CrEL) is a solubilizer used in paclitaxel and is associated with side effects (i.e., hypersensitivity reactions, peripheral neuropathy). Current CrEL-containing therapies require long infusion times (2-4 hours) and pre-medication with steroids to manage these side-effects. However, the holistic burden of CrEL on patients is not well studied. This study aimed to characterize the burden associated with CrEL-paclitaxel treatment on patients with ovarian cancer, including clinical, safety, and quality of life (QoL) implications.
Authors
Diana Brixner, Anke-Peggy Holtorf, Ayesha…
Read Now
Webinars
Available On Demand
Join Trinity Life Sciences for a webinar that explores the findings from our TGaS report entitled, ‘Reimagining Work Models in the Life Sciences: Implications for the Future of Work’. Life sciences companies have been examining policies and addressing how and where employees should work. Many lack objective sources of data to make informed decisions. TGaS led a study with a Commercial Operations department at a pharmaceutical company to help validate or debunk certain industry work-model assumptions.
Are you interested in…
Watch Now
White Papers
The Changing Work Model for Life Sciences.
When considering a work environment that will be sustainable in this new working world, life sciences companies have been examining policies and addressing how and where employees should work though lack objective sources of data to make informed decisions. The life sciences industry as a whole lacks work-model data. Like many organizations globally, certain work-model assumptions need to be validated or debunked. For example,
Employees should be at company headquarters if or when…
Read Now
